Q-omics provides the consensus-scored TGFBR1 profile across patient tissues and cancer cell-line models. TGFBR1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TGFBR1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, TGFBR1 protein abundance shows 35,009 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, HNSC, and PDAC as cancer lineages where TGFBR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TGFBR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TGFBR1 survival associations across molecular data types. TGFBR1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TGFBR1 RNA expression–survival associations across cancer types. High TGFBR1 expression shows unfavorable associations in ACC, MESO, BLCA, LGG and STAD, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TGFBR1 RNA expression.
This table summarizes TGFBR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TGFBR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TGFBR1 shows higher tumor expression in HNSC, THCA, LIHC, COAD, CHOL and READ. The HNSC box plot shows higher TGFBR1 RNA expression in tumor versus normal tissue (log2 FC = +1.557, t-test p < 0.001).
This table shows molecular features associated with TGFBR1 in patient tissues and cancer cell lines. In patient samples, TGFBR1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TGFBR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
